In the future, the association between BLM and novel drugs like anti-human CD25 (such as daclizumab) [42] or inhibitors of TGFβ signaling (such as Smad inhibitors) [43] may be beneficial for both anti-cancer efficacy and side-effect management. This evidence concerns the gene TGFB1 and cancer.